Delcath Systems, Inc. (NASDAQ:DCTH) CEO Gerard J. Michel acquired 15,500 shares of the business’s stock in a transaction on Monday, April 5th. The shares were bought at an average price of $12.88 per share, with a total value of $199,640.00. Following the completion of the transaction, the chief executive officer now directly owns 23,000 shares of the company’s stock, valued at $296,240. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NASDAQ DCTH opened at $14.00 on Thursday. Delcath Systems, Inc. has a 1-year low of $6.06 and a 1-year high of $25.18. The company has a 50 day moving average of $17.88 and a 200-day moving average of $17.31. The company has a market cap of $57.64 million, a price-to-earnings ratio of -0.01 and a beta of 0.83.
Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Tuesday, March 30th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.49. Research analysts predict that Delcath Systems, Inc. will post -6.8 earnings per share for the current year.
A number of large investors have recently made changes to their positions in DCTH. Silverarc Capital Management LLC bought a new position in Delcath Systems in the fourth quarter valued at approximately $6,301,000. Renaissance Technologies LLC bought a new position in Delcath Systems in the fourth quarter valued at approximately $1,815,000. AWM Investment Company Inc. bought a new position in Delcath Systems in the fourth quarter valued at approximately $1,559,000. Pura Vida Investments LLC bought a new position in Delcath Systems in the fourth quarter valued at approximately $1,165,000. Finally, Alyeska Investment Group L.P. bought a new position in Delcath Systems in the fourth quarter valued at approximately $889,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver.
Read More: Trading on Margin
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.